Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Status:
Not yet recruiting
Trial end date:
2031-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard
preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main
questions it aims to answer are:
- is T-DXd more effective than standard preoperative treatment?
- are there markers in the tumor or blood of patients with HER2-positive breast cancer
that can help us predict response to treatment?
Participants will be divided into two groups, where one group will be treated with three
courses of T-DXd and the other group will be treated with three courses standard of care
treatment. Thereafter, further treatment will be decided by the tumor's molecular subtype.